Better buy? Medibank Private Limited vs NIB Holdings Limited

Private health insurers are getting a lot of negative attention at the moment. Premiums have risen a lot faster than inflation over the last few years, but that’s mainly because health costs have also increased.

Health insurers are a good way of getting exposure to a lot of different health conditions rather than focusing on one particular issue like Cochlear Limited (ASX: COH).

The government has made it quite clear that the public health budget will come under increasing strain over the coming years and decades as Australia’s population ages further.

The government needs the private sector to take more of the burden to make the overall system more sustainable. Medibank Private Limited (ASX: MPL) has a big part to play as the largest private health insurer.

However, it appears to me that Medibank may not be the best choice on the ASX to get exposure to this trend.

In its latest report to 31 December 2016 it reported that its total number of policyholders fell by 1% and earnings per share grew by 1.9%. This isn’t a terrible result, but it’s not a good sign for the near future.

Medibank is currently trading at 18x FY17’s estimated earnings with a grossed-up dividend yield of 5.6%.

I think a better option could be NIB Holdings Limited (ASX: NHF). In its report to 31 December 2016 it disclosed that total policyholders grew by 6.4% and its statutory earnings per share grew by 65.7%.

NIB has a product setup with Qantas Airways Limited (ASX: QAN), called Qantas Assure, which is working well for both parties so far. NIB is smaller than Medibank so there is much more scope for it to grow market share and profit.

NIB is currently trading at 22x FY17’s estimated earnings with a grossed-up dividend yield of 4.2%. I think this seems far more attractive considering NIB’s recent and expected growth over the next two years.

Foolish takeaway

I think the private health insurance sector is a good place to be operating. However, the insurers will have to be mindful of the prices they are charging in case policyholders change to a competitor, or leave the private health insurance market altogether.

For more great growth stocks with similar potential to NIB, you should read this report prepared by our analysts for our latest ideas.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Tristan Harrison has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

HOT OFF THE PRESSES: My #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.